FibroGen (NASDAQ: FGEN) reported Q4 EPS of ($1.45), $0.79 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $16.5 million versus the consensus estimate of $47.65 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.